Side-by-side research comparison of Sermorelin and Tesamorelin across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 11 head-to-head studies plus 65 on Sermorelin and 23 on Tesamorelin.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Drug class | ghrh analog | ghrh analog |
| Studies in corpus | 65 | 23 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | other · 20 rct · 11 cohort · 1 in vitro · 10 review · 2 preclinical animal · 10 | other · 7 cohort · 1 rct · 7 review · 1 preclinical animal · 1 in vitro · 1 |
| Studies with explicit sample size | 6 | 1 |
| Head-to-head studies in corpus | 11 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Sermorelin and Tesamorelin batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 1049 Sermorelin batches across 399 manufacturers, 99.2% avg purity.
We tested 4946 Tesamorelin batches across 1316 manufacturers, 99.22% avg purity.
We hold deeper lab coverage on Tesamorelin (4946 batches tested). Tesamorelin edges ahead on average measured purity (99.2% vs 99.22%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both Sermorelin and Tesamorelin — the gold-standard direct comparison evidence.
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of its pharmacokinetic and pharmacodynamic…
This study is significant because it confirms the sustained efficacy and long-term safety of TH9507 (Tesamorelin) as a targeted treatment for HIV-associated lipodystrophy, a challenging side effect of ART. Reducing visceral adipose tissue (VAT) can alleviat…
The potential for Tesamorelin to augment exercise benefits in HIV-positive individuals is highly significant. If successful, this intervention could offer a novel and more effective strategy to combat frailty and physical decline in a population disproporti…
This highly sensitive detection method provides sports anti-doping agencies with a powerful new tool for identifying the use of prohibited GHRHs like CJC-1295. For athletes and individuals using these peptides, this significantly increases the probability o…
This study represents a significant advancement in the fight against doping in sports, specifically targeting growth hormone releasing hormone synthetic analogs. By identifying and characterizing previously unknown metabolites, it provides WADA-accredited l…
Understanding Tesamorelin's short-term effects in healthy individuals is crucial for broadening its potential therapeutic applications beyond HIV-associated lipodystrophy. If Tesamorelin can safely enhance GH secretion without impairing insulin sensitivity,…
The withdrawal of this study highlights a persistent gap in research for effective treatments for TBI-related insomnia, a condition that significantly impacts the quality of life for service members and veterans. Had it proceeded, a positive outcome could h…
This new comprehensive testing protocol represents a significant upgrade for anti-doping agencies. By enabling the simultaneous screening of numerous peptides like CJC-1295, insulins, and growth factors in a single run, it increases testing throughput and r…
Looking for vendor-level purity, endotoxin, and HPLC data on Sermorelin or Tesamorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.